Target
Pemetrexed
22 abstracts
Abstract
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Yunnan Cancer Hospital, Kunming, China, Sun Yat-sen University Cancer Center, Guang Zhou, China,
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,
Abstract
Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.Org: Osaka City General Hospital, Japanese Red Cross Okayama Hospital, Tosei General Hospital, Toyohashi Municipal Hospital, Matsunami General Hospital,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.Org: LungenClinic, N.N. Blokhin Russian Cancer Research Center, N.N. Petrov National Medical Research Center of Oncology, Thoracic Oncology Unit, Mid North Coast Cancer Institute,
Abstract
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.Org: Jiangmen, China,
Abstract
Five-year survival outcomes from the PIT-1 trial: Pemetrexed-cisplatin plus bevacizumab or concurrent thoracic radiation therapy followed by surgery in stage IIIA (N2) nonsquamous non-small cell lung cancer.Org: Juntendo University School of Medicine, Tokyo Bay Makuhari Clinic for Advanced Imaging, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,
Abstract
Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.Org: Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,
Abstract
Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.Org: Complutense University and CIBERONC, Tel-Aviv University Medical School, Central University Hospital of Asturias, Insular Maternal-Child University Hospital Complex of Gran Canaria, University of Las Palmas de Gran Canaria,
Abstract
Osimertinib related cardiotoxicity in patients with non-small cell lung cancer.Org: West Virginia University Camden Clark Medical Center, Morgantown, WVU Camden Clark Medical Center,
Abstract
Cost-efficiency and expanded access modeling of toripalimab versus pembrolizumab in locally advanced or metastatic nonsquamous non-small cell lung cancer.Org: Matrix45 LLC, Coherus Biosciences, University of Arizona of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, University of Arizona Cancer Center,
Abstract
Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.Org: Montgomery Regional Medical Campus,
Abstract
A retrospective study of tislelizumab combined with bevacizumab, pemetrexed, and carboplatin in driver-gene mutated advanced non-squamous non-small cell lung cancer after tyrosine kinase inhibitors failure.Org: The Second Affiliated Hospital of Zunyi Medical University,
Abstract
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).Org: Kobe Minimally Invasive Cancer Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan, Takarazuka City Hospital, Hyogo Medical University, Kurashiki Central Hospital, Kurashiki, Japan,
Abstract
Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China,
Abstract
Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.Org: Care Across,
Abstract
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.Org: Virginia Cancer Specialists, US Oncology Network, Mirati Therapeutics, Ontada,
Abstract
Clinical outcomes of chemotherapy rechallenge in patients with metastatic non-small cell lung (NSCLC) who progressed on immunotherapy maintenance after front line platinum doublets and immunotherapy.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center,
Abstract
Real-world treatment patterns of non-small cell lung cancer in an Indian hospital.Org: Mango Sciences, Inc., Boston Pharmaceuticals, MaaT Pharma, Subhash Nagar, Nelamangala,
Abstract
ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).Org: Valkyrie Clinical Trials, Inc, Rocky Mountain Cancer Centers, Millennium Oncology, Virginia Cancer Specialists, Genprex,
Abstract
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China, Guangdong Provincial People's Hospital,